

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial

J Brooks Jackson, MD, Philippa Musoke, MBChB, Thomas Fleming, PhD, Laura A Guay, MD, Danstan Bagenda, MSc, Melissa Allen, MPH, Clemensia Nakabiito, MBChB, Joseph Sherman, MD, Paul Bakaki, MBChB, Maxensia Owor, MBChB, Constance Ducar, BS, Martina Deseyve, Dipl Math, Anthony Mwatha, MS, Lynda Emel, PhD, Corey Duefield, MPH, Mark Mirochnick, MD, Mary Glenn Fowler, MD, Lynne Mofenson, MD, Paolo Miotti, MD, Maria Gigliotti, MS, Dorothy Bray, PhD and Francis Mmiro, FRCOG


The Lancet

[Volume 362, Issue 9387, Pages 859-868](#) (September 2003)

DOI: 10.1016/S0140-6736(03)14341-3




Figure 1



Source: [The Lancet 2003; 362:859-868](#) (DOI:10.1016/S0140-6736(03)14341-3)

[Terms and Conditions](#)


Figure 2



Source: [The Lancet 2003; 362:859-868](#) (DOI:10.1016/S0140-6736(03)14341-3)

[Terms and Conditions](#)

Figure 3



Numbers at risk

Zidovudine infected	59	56	52	49	47	45	42	39	37	35
Nevirapine infected	36	36	35	34	31	29	27	25	24	23
Zidovudine uninfected	249	236	231	228	225	218	218	213	212	209
Nevirapine uninfected	275	264	261	260	258	252	251	249	247	241